ScharschmidtTCYostJMTruongSVSteinhoffMWangKCBergerTG. Neurogenic Rosacea: A Distinct Clinical Subtype Requiring a Modified Approach to Treatment. Arch Dermatol. 2010;147(1):123. doi:10.1001/archdermatol.2010.413
2.
WeiJWanMChenQ, et al. Gabapentin is an efficacy treatment for facial flushing and erythema of erythematotelangiectatic rosacea: A randomized clinical noninferiority trial. J Am Acad Dermatol. Published online December 2024:S0190962224033784. doi:10.1016/j.jaad.2024.12.011
3.
WangBHuangYTangY, et al. Paroxetine is an effective treatment for refractory erythema of rosacea: Primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial. J Am Acad Dermatol. 2023;88(6):1300-1307. doi:10.1016/j.jaad.2023.01.044
4.
KimHOKangSYKimKEChoSYKimKHKimI. Neurogenic rosacea in Korea. J Dermatol. 2021;48(1):49-55. doi:10.1111/1346-8138.15629
5.
HurtadoDICPérezAPCLópezRFR. Neurogenic rosacea successfully treated with neuromodulators and intense pulsed light. An Bras Dermatol. 2024;99(2):296-297. doi:10.1016/j.abd.2022.09.016
6.
ChiuIHTsaiTF. Use of cyclosporine in the treatment of patients with possible neurogenic rosacea presenting as persistent facial edema with burning sensation: A case series. Dermatol Sin. 2024;42(1):58-59. doi:10.4103/ds.DS-D-23-00041
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
